Tamoxifen Initiation After Ductal Carcinoma In Situ
- Nichols, Hazel B.
- Bowles, Erin J. A.
- Islam, Jessica
- Madziwa, Lawrence
- Stürmer, Til
- Tran, Diem-Thy
- Buist, Diana S. M.
DOIAbstract
Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after DCIS over a 15-year period in an integrated health care setting to identify factors related to initiation
Add to ORKG